Lupin

Which are the latest news on Lupin?

Why is Lupin Ltd. falling/rising?

As of 05-Sep, Lupin Ltd. is facing a stock price decline to 2,111.00, down -1.12%, and has underperformed its sector. The stock is trading below its moving averages, indicating a bearish trend, despite strong long-term growth fundamentals.

As of 05-Sep, Lupin Ltd. is experiencing a decline in its stock price, currently at 2,111.00, which reflects a change of -24.0 or -1.12%. This downward movement is evident as the stock has underperformed its sector by -0.67% today and has been on a consecutive fall for the last two days, accumulating a total decline of -1.93% during this period.<BR><BR>The stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by -15.67% compared to the 5-day average, suggesting reduced interest from investors.<BR><BR>Despite these negative indicators, it is important to note that Lupin Ltd. has shown strong long-term growth fundamentals, with net sales increasing at an annual rate of 13.51% and operating profit at 29.96%. However, the current market sentiment appears to be overshadowing these positive aspects, contributing to the stock's decline.

Who are in the management team of Lupin?

The management team of Lupin includes M D Gupta (Chairman), Nilesh Deshbandhu Gupta (Managing Director), Vinita Gupta (CEO), R V Satam (Company Secretary), and several independent directors including Jean-Luc Belingard, Mark D McDade, K B S Anand, and Punita Kumar Sinha, along with Ramesh Swaminathan (CFO). This team offers a diverse range of expertise and leadership.

The management team of Lupin includes the following key members:<BR><BR>1. **M D Gupta** - Chairman (Non-Executive)<BR>2. **Nilesh Deshbandhu Gupta** - Managing Director<BR>3. **Vinita Gupta** - Director & Chief Executive Officer<BR>4. **R V Satam** - Company Secretary & Compliance Officer<BR>5. **Jean-Luc Belingard** - Independent Director<BR>6. **Ramesh Swaminathan** - Executive Director & Chief Financial Officer<BR>7. **Mark D McDade** - Independent Director<BR>8. **K B S Anand** - Independent Director<BR>9. **Punita Kumar Sinha** - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Lupin do?

Lupin Ltd. is a global pharmaceutical company that develops and markets branded and generic drugs, biotechnology products, and APIs. As of June 2026, it reported net sales of ₹8,277 Cr and a net profit of ₹1,415 Cr, with a market cap of ₹98,587 Cr.

Overview: <BR>Lupin Ltd. is an innovation-led transnational pharmaceutical company that produces, develops, and markets a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Mid Cap.<BR><BR>History: <BR>Lupin was incorporated in 1968 and has since evolved in the pharmaceutical sector. The latest quarterly results reported are for June 2026, showcasing the company's performance in net sales and profit.<BR><BR>Financial Snapshot: <BR>- Net Sales: 8,277 Cr (Quarterly Results - Jun 2026) <BR>- Net Profit: 1,415 Cr (Quarterly Results - Jun 2026) <BR>- Market Cap: INR 98,587 Cr (Mid Cap) <BR><BR>Key Metrics: <BR>- P/E: 17.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.83% <BR>- Debt Equity: -0.12 <BR>- Return on Equity: 25.68% <BR>- Price to Book: 4.43 <BR><BR>Contact Details: <BR>Address: Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E Mumbai Maharashtra : 400055 <BR>Tel: 91-22-6640 2323 <BR>Email: info@lupin.com <BR>Website: http://www.lupin.com

Who are the peers of the Lupin?

Lupin's peers include Torrent Pharma, Zydus Lifesci, Cipla, Laurus Labs, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Glenmark Pharma, Biocon, and Alkem Lab. In terms of performance, Laurus Labs leads with a 1-year return of 122.69%, while Lupin has a return of 15.05%, higher than Cipla's -10.92%.

Peers: The peers of Lupin are Torrent Pharma, Zydus Lifesci., Cipla, Laurus Labs, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Glenmark Pharma, Biocon, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Torrent Pharma, Zydus Lifesci., Cipla, Laurus Labs, Dr Reddy's Labs, Mankind Pharma, Glenmark Pharma, and the rest. Growth is excellent at Zydus Lifesci. and Lupin, while average growth is found at Torrent Pharma and Dr Reddy's Labs, and below average growth is noted at Cipla, Laurus Labs, Aurobindo Pharma, and the rest. Excellent capital structure is seen at Zydus Lifesci., Cipla, Mankind Pharma, and Aurobindo Pharma, while good capital structure is observed at Torrent Pharma, Lupin, Glenmark Pharma, and the rest, and below average capital structure is noted at Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 122.69%, while Cipla has the lowest at -10.92%. Lupin's 1-year return of 15.05% is higher than Cipla's but lower than Laurus Labs'. Additionally, Dr Reddy's Labs and Biocon have negative six-month returns.

How big is Lupin?

As of 31st August, Lupin Ltd. has a market capitalization of 98,587.00 Cr, with recent net sales of 29,966.58 Cr and a net profit of 5,528.81 Cr. The company reported shareholder's funds of 22,448.27 Cr and total assets of 37,800.11 Cr.

As of 31st August, Lupin Ltd. has a market capitalization of 98,587.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Lupin reported Net Sales of 29,966.58 Cr and a Net Profit of 5,528.81 Cr.<BR><BR>For the latest annual period, the company reported Shareholder's Funds of 22,448.27 Cr and Total Assets of 37,800.11 Cr.

Should I buy, sell or hold Lupin Ltd.?

When is the next results date for Lupin Ltd.?

The next results date for Lupin Ltd. is 06 August 2026.

The next results date for Lupin Ltd. is scheduled for 06 August 2026.

Are Lupin Ltd. latest results good or bad?

Lupin Ltd.'s latest Q4 FY26 results are strong, with a net profit increase of 89.04% year-over-year and revenue growth of 31.89%. The improved operating margin and return on equity indicate robust performance and a positive outlook for future growth.

Lupin Ltd.'s latest results for Q4 FY26 are quite strong, showcasing significant growth and improved profitability. The company reported a net profit of ₹1,460.34 crores, which is an impressive 89.04% increase year-over-year. Revenue also saw a substantial rise, reaching ₹7,474.66 crores, marking a 31.89% year-over-year growth. <BR><BR>Additionally, the operating margin expanded to 33.63%, up from 31.86% in the previous quarter and significantly higher than the 23.75% recorded in the same quarter last year. This indicates improved operational efficiency and pricing power. The return on equity (ROE) is also noteworthy at 22.03%, reflecting excellent capital efficiency.<BR><BR>Overall, these results suggest that Lupin is in a strong position, with robust growth in both revenue and profit, making the latest performance good. The company's focus on operational excellence and strategic product launches appears to be paying off, contributing to a positive outlook for future growth.

Is Lupin technically bullish or bearish?

As of November 28, 2025, Lupin's technical trend has shifted to bullish, supported by strong indicators such as a bullish MACD, Bollinger Bands, and moving averages, along with a recent price action that exceeds the previous close.

As of 28 November 2025, the technical trend for Lupin has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also indicate a bullish trend. The KST shows a bullish signal on the weekly timeframe, while the Dow Theory reflects a mildly bullish stance on both weekly and monthly timeframes. The OBV is mildly bullish on the weekly and bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the recent price action, with today's high surpassing the previous close.

How has been the historical performance of Lupin?

Lupin has shown significant growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 14,664.56 Cr to 22,707.90 Cr and profit after tax rising from 517.27 Cr to 3,306.26 Cr, indicating strong operational efficiency and recovery. Total assets and liabilities also grew, reflecting balanced financial health.

Answer:<BR>The historical performance of Lupin shows a significant upward trend in net sales and profitability over the past few years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Lupin's net sales have steadily increased from 14,664.56 Cr in March 2019 to 22,707.90 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar pattern, rising from 14,664.56 Cr in March 2019 to 22,707.90 Cr in March 2025. The total expenditure, excluding depreciation, also grew from 12,103.84 Cr in March 2019 to 17,424.59 Cr in March 2025, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) saw a remarkable rise from 2,560.72 Cr in March 2019 to 5,479.13 Cr in March 2025, showcasing improved operational efficiency. Profit before tax surged from 1,405.21 Cr in March 2019 to 4,015.00 Cr in March 2025, while profit after tax increased from 517.27 Cr to 3,306.26 Cr during the same period. The consolidated net profit also reflected this positive trend, climbing from 606.55 Cr in March 2019 to 3,281.62 Cr in March 2025. Additionally, the company's total assets rose from 24,809.54 Cr in March 2020 to 28,645.78 Cr in March 2025, while total liabilities increased from 24,809.54 Cr to 28,645.78 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching 2,999.00 Cr in March 2025, despite a negative cash flow from investing activities of -4,171.00 Cr, which suggests substantial investments in growth initiatives. Overall, Lupin's financial performance demonstrates a strong recovery and growth phase, particularly in the last fiscal year.

Is Lupin overvalued or undervalued?

As of November 7, 2025, Lupin is considered fairly valued with a PE ratio of 20.82, an attractive valuation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -16.17%, supported by strong ROCE and ROE metrics.

As of 7 November 2025, Lupin's valuation grade has moved from very attractive to attractive. The company is currently considered fairly valued. Key ratios include a PE ratio of 20.82, an EV to EBITDA of 13.53, and a PEG ratio of 0.32, indicating strong growth potential relative to its price. <BR><BR>In comparison to its peers, Lupin's valuation appears more favorable; for instance, Sun Pharma has a PE ratio of 35.17 and Divi's Lab stands at 71.11, both categorized as expensive. Other attractive peers include Cipla with a PE of 22.33 and Dr. Reddy's Labs at 17.43. Despite a challenging year-to-date return of -16.17% compared to the Sensex's 6.50%, Lupin's solid ROCE of 22.16% and ROE of 19.08% suggest it remains a robust investment in the pharmaceuticals sector.

Who are the top shareholders of the Lupin?

The top shareholders of Lupin include Lupin Investments Pvt Ltd with 45.38%, institutional investors with 38 mutual fund schemes holding 17.55% and 872 foreign institutional investors holding 21.46%, and HDFC Trustee Company Ltd as the highest public shareholder at 3.22%. Individual investors account for 5.1% of the holdings.

The top shareholders of Lupin include the promoters, with Lupin Investments Pvt Ltd holding the largest stake at 45.38%. Additionally, institutional investors play a significant role, with 38 mutual fund schemes collectively holding 17.55% and 872 foreign institutional investors (FIIs) holding 21.46%. The highest public shareholder is HDFC Trustee Company Ltd through the HDFC Balanced Advantage Fund, which holds 3.22%. Individual investors account for 5.1% of the holdings.

What is the bonus history of the Lupin?

Lupin Ltd. announced a 1:1 bonus issue on August 11, 2006, with a record date of August 14, 2006, allowing shareholders to receive an additional share for each share owned.

Lupin Ltd. has a bonus history that includes a notable 1:1 bonus issue announced on August 11, 2006. The record date for this bonus was August 14, 2006. This means that shareholders on record as of that date received an additional share for each share they owned.

Has Lupin declared dividend?

Yes, Lupin Ltd. has declared a 400% dividend, amounting to ₹8 per share, with an ex-date of July 16, 2024. Despite a recent 6.04% decline in the last 6 months, the company has shown strong total returns over longer periods, particularly a 234.26% return over the past 3 years.

Lupin Ltd. has declared a 400% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 400%<BR>- Amount per share: 8<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.4%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -6.04%, with a dividend return of 0%, resulting in a total return of -6.04%.<BR><BR>Over the past year, the price return was 24.64%, the dividend return was 0.50%, leading to a total return of 25.14%.<BR><BR>In the 2-year period, the price return reached 143.95%, with a dividend return of 1.45%, culminating in a total return of 145.4%.<BR><BR>For the last 3 years, the price return was 231.65%, the dividend return was 2.61%, resulting in a total return of 234.26%.<BR><BR>Over the past 4 years, the price return stood at 62.73%, with a dividend return of 1.93%, leading to a total return of 64.66%.<BR><BR>In the 5-year period, the price return was 122.08%, the dividend return was 3.18%, resulting in a total return of 125.26%.<BR><BR>Overall, Lupin Ltd. has declared a substantial dividend, and the total returns over various periods indicate a generally positive performance, particularly in the longer-term horizons, despite a recent decline in the short term.